Accelerated Pharma (Accelerated Pharma) Cost of Goods Sold : $0.00 Mil (TTM As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Cost of Goods Sold?

Accelerated Pharma's cost of goods sold for the three months ended in Mar. 2017 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2017 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Accelerated Pharma's Gross Margin % for the three months ended in Mar. 2017 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.

Accelerated Pharma Cost of Goods Sold Historical Data

The historical data trend for Accelerated Pharma's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Cost of Goods Sold Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Cost of Goods Sold

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Cost of Goods Sold	Get a 7-Day Free Trial			-	-	-	-	-

Accelerated Pharma Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Accelerated Pharma (NAS:ACCP) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Accelerated Pharma's Gross Margin % for the three months ended in Mar. 2017 is calculated as:

Gross Margin %	=	(Revenue	-	Cost of Goods Sold)	/	Revenue
	=	(0	-	0)	/	0
	=	%

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Accelerated Pharma's Inventory Turnover for the three months ended in Mar. 2017 is calculated as:

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.

Accelerated Pharma Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Cost of Goods Sold

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines